Clinical trial

A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

NCT01052194

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention VX-509 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-02-01

PhasePHASE2

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

PlaceboDRUG

VX-509DRUG

Sponsors & collaborators

Vertex Pharmaceuticals Incorporatedlead sponsor

Mapped research locations

TampaFlorida, United States2 DallasTexas, United States1 St LouisMissouri, United States1 BirminghamAlabama, United States1 Oklahoma CityOklahoma, United States1 CharlestonSouth Carolina, United States1 CharlotteNorth Carolina, United States1 BudapestHungary1 HamburgGermany1 BucharestRomania1 SpokaneWashington, United States1 San JuanPuerto Rico1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01052194 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.